A Study to Investigate Relative Bioavailability of Two Different Dosage Forms for Tozorakimab Via Subcutaneous Administration in Healthy Volunteers

A Randomised, Single-dose, Parallel Group Study in Healthy Volunteers to Assess the Relative Bioavailability of Two Different Dosage Forms for Tozorakimab Via Subcutaneous Administration

The study will assess the relative bioavailability between two dosage forms of tozorakimab (test dosage form and reference dosage form) and to assess the pharmacokinetic (PK) profiles of both dosage forms.

Study Overview

• Status: Recruiting
• Conditions: Healthy Participants
• Intervention / Treatment: Biological: Tozorakimab

Detailed Description

This is a phase I, randomised, open-label, single-dose, single-centre, parallel group study investigating the relative bioavailability of two dosage forms of tozorakimab (test dosage form and reference dosage form).

The study will comprise of:

1. A screening period of 28 days
2. A Treatment period of 1 day
3. Ambulatory visits on scheduled days

c. A final follow-up visit on Day 113 (Week 16)

• Study Type: Interventional
• Enrollment (Estimated): 46
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: AstraZeneca Clinical Study Information Center; Phone Number: 1-877-240-9479; Email: information.center@astrazeneca.com

Study Locations

• Germany
  • Berlin, Germany, 14050
    • Recruiting
    • Research Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Healthy male and female participants aged 18 to 55 years.
• All females must have a negative pregnancy test at the screening visit and on admission to the Clinical Unit.
• Females of childbearing potential must not be lactating and, if heterosexually active, must agree to use an approved method of highly effective contraception.
• Females of non-childbearing potential must be confirmed at the screening visit.
• Sexually active fertile male participants with partners of childbearing potential must adhere to the contraception methods.
• Have a body mass index (BMI) between 19 and 30 kg/m2 inclusive and weigh at least 55 kg and no more than 100 kg inclusive.
• Intact normal skin without potentially obscuring tattoos, scars, etc, at the injection site.

Exclusion Criteria:

• History of any clinically significant disease or disorder (including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, hematological, psychiatric, or major physical impairment that is not stable in the opinion of the investigator).
• Any clinically significant abnormal findings in vital signs at the screening visit and/or admission (Day -1) to the Clinical Unit, as judged by the investigator.
• Any clinically significant abnormalities on 12-lead ECG at the screening visit and/or admission (Day -1) to the Clinical Unit, as judged by the investigator.
• Current smokers or those who have smoked or used nicotine products (including e-cigarettes) within the previous 6 months prior to the screening visit, as judged by the investigator.
• Any clinically important illness, medical/surgical procedure, or trauma within 8 weeks of the screening visit, or any planned inpatient surgery or hospitalisation during the study period.
• Malignancy, current or within the past 5 years, except for adequately treated non-invasive basal cell and squamous cell carcinoma of the skin and cervical carcinoma-in-situ treated with apparent success more than 1 year prior to enrolment. Suspected malignancy or undefined neoplasms.
• Suspicion of, or confirmed, ongoing SARS-CoV-2 infection.
• Any laboratory values with the following deviations at the screening visit or on admission (Day -1) to the Clinical Unit.
• Any clinically significant abnormal findings in physical examination at screening and/or admission (Day -1), which, in the opinion of the investigator, may put the participant at risk because of their participation in the study or may influence the results of the study, or the participant's ability to complete the entire duration of the study.
• History of known immunodeficiency disorder, including a positive test for Human immunodeficiency virus-1 (HIV-1) or HIV-2.
• History or treatment for hepatitis B or hepatitis C or any positive test result on screening for Hepatitis B surface antigen (HBsAg), anti- Hepatitis B core (HBc) antibodies, or anti-hepatitis C antibodies.
• Evidence of active or latent Tuberculosis (TB).

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Tozorakimab Dosage form A (Test); Participants will receive a single dose of Tozorakimab Dosage form A via subcutaneous (SC) injection.	Biological: Tozorakimab; Tozorakimab will be administered as a single SC dose on Day 1.
Experimental: Tozorakimab Dosage form B (Reference); Participants will receive a single dose of Tozorakimab Dosage form B via SC injection.	Biological: Tozorakimab; Tozorakimab will be administered as a single SC dose on Day 1.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Area under the concentration-time curve from time 0 to infinity (AUCinf)	To evaluate the relative bioavailability of two different dosage forms of tozorakimab (test and reference).	Day 1 (Pre-dose), Days 3, 4, 5, 7, 8, 9, 15, 29, 43, 57, 85 and 113 (Post-dose).
Area under the concentration-curve from time 0 to the last quantifiable concentration (AUClast)	To evaluate the relative bioavailability of two different dosage forms of tozorakimab (test and reference).	Day 1 (Pre-dose), Days 3, 4, 5, 7, 8, 9, 15, 29, 43, 57, 85 and 113 (Post-dose).
Maximum observed drug concentration (Cmax)	To evaluate the relative bioavailability of two different dosage forms of tozorakimab (test and reference).	Day 1 (Pre-dose), Days 3, 4, 5, 7, 8, 9, 15, 29, 43, 57, 85 and 113 (Post-dose).

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Time to reach peak or maximum observed concentration following tozorakimab administration (tmax)	To examine the tmax of two different dosage forms of tozorakimab (test and reference).	Day 1 (Pre-dose), Days 3, 4, 5, 7, 8, 9, 15, 29, 43, 57, 85 and 113 (Post-dose).
Terminal elimination half-life (t1/2)	To examine the t1/2 of two different dosage forms of tozorakimab (test and reference).	Day 1 (Pre-dose), Days 3, 4, 5, 7, 8, 9, 15, 29, 43, 57, 85 and 113 (Post-dose).
Terminal rate constant (λz)	To examine the λz of of two different dosage forms of tozorakimab (test and reference).	Day 1 (Pre-dose), Days 3, 4, 5, 7, 8, 9, 15, 29, 43, 57, 85 and 113 (Post-dose).
Apparent total body clearance (CL/F)	To examine the CL/F of two different dosage forms of tozorakimab (test and reference).	Day 1 (Pre-dose), Days 3, 4, 5, 7, 8, 9, 15, 29, 43, 57, 85 and 113 (Post-dose).
Apparent volume of distribution based on the terminal phase (Vz/F)	To examine the Vz/F of two different dosage forms of tozorakimab (test and reference).	Day 1 (Pre-dose), Days 3, 4, 5, 7, 8, 9, 15, 29, 43, 57, 85 and 113 (Post-dose).
Number of participants with adverse events (AEs)	To assess the safety and tolerability of a single dose of tozorakimab administered subcutaneously via two different dosage forms in healthy participants.	From screening (Day -28) to last follow-up visit (Day 113- approximately 21 weeks).
Number of participants with presence of Anti-Drug Anitbodies (ADAs)	To evaluate the immunogenicity of a single dose of tozorakimab administered subcutaneously via two different dosage forms in healthy participants.	Day 1 (Pre-dose), Days 29, 57 and 113 (Post-dose).

Collaborators and Investigators

• Sponsor: AstraZeneca

Study record dates

Study Major Dates

• Study Start (Actual): April 8, 2024
• Primary Completion (Estimated): September 5, 2024
• Study Completion (Estimated): September 5, 2024

Study Registration Dates

• First Submitted: March 5, 2024
• First Submitted That Met QC Criteria: March 5, 2024
• First Posted (Actual): March 12, 2024

Study Record Updates

• Last Update Posted (Actual): April 23, 2024
• Last Update Submitted That Met QC Criteria: April 22, 2024
• Last Verified: April 1, 2024

More Information

Terms related to this study

• Keywords: Asthma; Pharmacokinetics; Bioavailability; Chronic Obstructive Pulmonary Disease; Human immunoglobulin G1 monoclonal antibody
• Other Study ID Numbers: D9180C00011

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES

IPD Plan Description

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

"Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

• IPD Sharing Time Frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
• IPD Sharing Access Criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No